GOVERNANCE & COMPLIANCE

TERMS & CONDITIONS

EFFECTIVE JANUARY May 24, 2024

Terms & Conditions

These Terms & Conditions govern access to and use of the Journal of Grab Medical Innovations, including manuscript submission, publication, licensing, and related services.

Last Formal RatificationMay 24, 2024

Applicable JurisdictionSwiss CO / Swiss Civil Code (CC)

Commercial Fee Surcharge$0.00 (Zero APC Mandate)

Plain Language Executive Summary

READ BEFORE ACCEPTINGPLAIN LANGUAGEQUICK REFERENCE

These Terms & Conditions explain the rules that apply when accessing or using the Journal of Grab Medical Innovations and its related services.

In simple terms: authors, reviewers, editors, and readers are expected to follow the applicable submission, publication, licensing, and conduct requirements described in this document.

The formal terms below remain legally controlling. This summary is provided to make the principal obligations easier to understand and navigate.

Plain-language access

Key terms are explained clearly for all readers.

Transparent obligations

Responsibilities and requirements are clearly stated.

Zero APC mandate

No article processing surcharge is applied.

1LEGAL ENTITY, PREAMBLE & FOUNDATION SCOPE

Effective May 24, 2024

Legal Entity, Preamble & Foundation Scope

The Journal of Grab Medical Innovations (JGMI) is a peer-reviewed international scientific publication operated by Grab Medical Innovations.

The Journal exists to facilitate the open, rigorous, and permanent dissemination of scientific knowledge. These Terms and Conditions govern access to the Journal, submission of manuscripts, publication of research, use of the digital repository, and citation of archived materials.

The constitutional purpose of JGMI is the unfettered international publication, archiving, and dissemination of breakthrough peer-reviewed research in clinical robotics, translational neuro-oncology, autonomous surgical engineering, and clinical informatics. By submitting manuscripts, accessing the digital repository, or citing archived data, the User agrees to be legally bound by these terms in full conformity with the Swiss Code of Obligations (CO) and governing international intellectual property conventions.

2OPEN ACCESS POLICY & AUTHOR COPYRIGHT RETENTION

Effective May 24, 2024

Diamond Open Access Policy & Author Copyright Retention

The Journal of Grab Medical Innovations (JGMI) operates under a Diamond Open Access model, ensuring that research remains freely accessible to readers without financial barriers.

No Article Processing Charges

Neither authors, academic departments, hospitals, nor philanthropic grant-makers are ever invoiced Article Processing Charges (APCs), submission evaluation fees, editorial handling tariffs, color illustration fees, or perpetual digital repository preservation levies. Publication is funded solely via Foundation endowment trust capital.

Author Copyright Retention

Authors retain unconditional, unencumbered moral and statutory copyright of their original texts, illustrations, surgical algorithms, and clinical datasets. Upon acceptance, authors grant the Foundation a non-exclusive, irrevocable, worldwide, perpetual license to format, index, register with Crossref/PubMed Central, and permanently host the Version of Record (VoR).

3CREATIVE COMMONS CC BY-NC 4.0

Effective May 24, 2024

Creative Commons CC BY-NC 4.0 Detailed Scope

Unless otherwise expressly stated, all published works are made available under the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0) license. This permits broad educational and research use while protecting the work from unauthorized commercial exploitation.

Permitted Uses

Educational & Clinical Dissemination: Sharing, reproducing, and distributing the work for educational and clinical purposes, provided that appropriate attribution is maintained.
Translation & Clinical Protocols: Translating published material and incorporating it into clinical protocols, educational resources, and non-commercial research workflows with proper attribution.
Non-Commercial Machine Learning: Using the licensed material for non-commercial machine-learning research, model development, evaluation, and academic experimentation.
Institutional Repositories: Depositing and preserving published work in institutional, academic, or public repositories while maintaining the original attribution and license information.

Prohibited Uses

Commercial Resale & Paywalling: Reselling the work, placing it behind a commercial paywall, or otherwise monetizing access to the licensed material.
Commercial Pharmaceutical Promotion: Using the published material for commercial pharmaceutical promotion, advertising, product endorsement, or marketing activities.
Removal of DOI / Attribution: Removing, obscuring, altering, or misrepresenting the DOI, author attribution, publication information, or applicable Creative Commons license.
Monetized Closed-Weight AI Systems: Using the licensed material to train or develop monetized closed-weight AI systems where the resulting system is not made available under compatible licensing terms.

4AUTHOR REPRESENTATIONS, ORIGINALITY & ETHICAL UNDERTAKINGS

Effective May 24, 2024

Author Representations, Originality & Ethical Undertakings

By submitting an article to JGMI, the corresponding author and all named co-authors warrant and represent jointly and severally that:

Originality & Prior Publication

The manuscript is an authentic work of original scientific inquiry, has not been published elsewhere in whole or substantial part, and is not currently under parallel review by another peer-reviewed venue.

Authorship & AI Attribution

Ghost authorship, honorary guest authorship, and attribution of co-authorship to generative artificial intelligence (LLMs) are strictly prohibited. AI usage in statistical analysis must be disclosed with tool versioning.

Ethics & Human Research

All clinical trials, observational human cohorts, and surgical bio-specimen research carry documented Institutional Review Board (IRB) or Independent Ethics Committee approval numbers alongside informed patient consent records conforming to the Declaration of Helsinki.

Conflicts of Interest

Authors certify the transparent declaration of all commercial, pharmaceutical, venture equity, patent-holding, and institutional conflicts of interest within the preceding 36-month period on official ICMJE forms.

5READER RIGHTS & SCHOLARLY TEXT AND DATA MINING (TDM)

Effective May 24, 2024

Reader Rights & Scholarly Text and Data Mining (TDM)

JGMI provides unconditional, instant read-access to the international public. No institutional proxy authentication, subscription gate, or per-article purchase is required. Readers have the right to read, download, copy, distribute, print, search, or link to the full texts of all articles.

6PLATFORM RELIABILITY & PERMANENT DIGITAL PRESERVATION

Effective May 24, 2024

Platform Reliability & Permanent Digital Preservation

The Foundation provides uninterrupted high-availability web dissemination through geo-redundant medical cloud clusters. To guarantee eternal availability regardless of geopolitical or operational disruptions:

CLOCKSS Preservation

Full JATS-XML texts, supplementary video data, and high-resolution surgical imagery are mirrored continuously in CLOCKSS nodes worldwide.

Institutional Continuity

In the event of institutional restructuring or foundation dissolution, all published literature automatically triggers open-access release across Portico academic library networks.

7GOVERNING LAW, OMBUDSMAN MEDIATION & SWISS JURISDICTION

Effective May 24, 2024

Governing Law, Ombudsman Mediation & Swiss Jurisdiction

These Terms, all publication agreements, and any non-contractual obligations arising out of or in connection with the Journal shall be governed by and construed in accordance with the substantive laws of Switzerland, specifically the Swiss Code of Obligations (Obligationenrecht), excluding its conflict of laws provisions.

Official Institutional Ratification

Ratification & Legal Sign-Off

Institutionally Ratified

These Terms of Service and Open Access Bylaws were formally approved and enacted by unanimous vote of the Board of Trustees and the International Scientific Directorate of the Grab Medical Innovations Research Foundation on May 24, 2024.

CEO of GrabMedin

Dr. Khalid Munir Bhatti

Editor-in-Chief • Scientific Directorate

Grab Medical Innovations Research Foundation

Questions regarding these Terms or institutional ratification?

Contact the Journal Administration